Blog

Exploring the future of De-centralized and Hybrid Trials: Huma at SCOPE 2023

February 24, 2023
Blog

Exploring the future of De-centralized and Hybrid Trials: Huma at SCOPE 2023

February 24, 2023

Dennis Velasquez

VP, Commercial, DCT

This is some text inside of a div block.
mins read
Speaker shot.

Speaker shot.

Speaker shot.

On the 6th February we saw the opening of SCOPE 2023 in Orlando, a summit for clinical ops executives and an opportunity to learn about the latest developments in decentralised clinical trials (DCT). Huma's DCT team was present at the event and shared insights on how digital is paving the way for DCTs. Themes from the event focused on the advancements of  innovative solutions in all aspects of clinical trials ranging from planning, management and operations. Attendees had the chance to learn and network with leading experts in the field and gain valuable insights into how to execute successful decentralised and hybrid trials.

We caught up Huma’s DCT team to get their take-home points from the event.

“Our presence this year certainly broadened our reach to potential new clients and partners globally, and it provided us with an excellent platform to improve market awareness of Huma as a provider of DCT and hybrid solutions.”

Clare Burn, DCT Huma

What was your impression of SCOPE this year? 

This year's event was one of the most well-attended events yet with a diverse range of attendees from around the world. It’s an opportunity to bring together industry leaders, thought leaders, and innovators to discuss the latest developments in decentralised clinical trials. 

The atmosphere at SCOPE was electric, with networking opportunities and thought-provoking conversations with high level executives across the biopharma and life science industries. The agenda was packed with engaging talks from industry experts who shared their insights on decentralised protocols, data, real-world evidence and operations. It was an incredible experience for everyone involved and many delegates left the event feeling inspired and energized.

Clare Burn, DCT Huma said “SCOPE this year was well attended by delegates from across different industries, we were impressed by the sheer scale of the event! Our presence this year certainly broadened our reach to potential new clients and partners globally, and it provided us with an excellent platform to improve market awareness of Huma as a provider of DCT and hybrid solutions. We couldn’t be happier with the level of engagement and interest that the Huma team received - It was a great opportunity to gain insights that will serve to improve our offering.” 

What were some of the themes that you took away from the event?

It’s clear from many of the talks that the industry is still solving the conundrum of introducing new technologies and solutions that work for the sponsor, site, and patient.

Dhruv Wadhwa, DCT Huma said “Currently, sites still wish to control the direct relationship with the patient and this is affecting DCT vendors ability to provide remote patient monitoring solutions without the right balance of control and visibility being given to the site. We’re also seeing the entry of new site vendors such as Walgreens and CVS and this is being countered by traditional sites who question their operational experience. While these newer players tout scalable capacity, the studies they engage in are still small in scope, with details such as site capabilities, feasibility and patient recruitment still being ironed out.”  

Some other key themes from the event included reducing site burden, increasing patient diversity and solving the friction between stakeholders that can often lead to a slow in the implementation and adoption of new technologies. A number of panels were focused on the importance of collaboration between different organisations and examined how technological advances can help to improve patient outcomes and reduce the burden on sites in the research process.

“Highlighting our digital expertise which is complimented but the capabilities we recently acquired with Alcedis, coming together to produce an enhanced DCT offering.”

Dennis Velasquez VP DCT, Huma

This field is required
Email must be formatted correctly
This field is required
This field is required
This field is required

Huma is committed to respecting your privacy, we’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes. You can unsubscribe at any time. Review our Privacy Policy for further information.

Keep up to date on our current work and research with the latest marketing updates from Huma, including monthly news, events and communications on products and services.

By clicking submit below, you consent to allow Huma to store and process the personal information submitted above to provide you the content requested.

One of our team members will be in touch with you shortly.
Oops! Something went wrong while submitting the form.

What opportunities were there to connect with delegates and exhibitors? 

We were able to connect with decisions makers and key sponsors from across the industry. These conversations facilitated a better understanding of their approach to solve many of the challenges facing clinical research and the processes involved in running trials. It was also a great opportunity to hear from other solution providers to understand the market as a whole, the barriers to new technological advances and where there might be a chance to collaborate. 

Dennis Velasquez VP DCT, Huma said “Many of the people in attendance hold the responsibility for driving innovation and digital strategies within their area of clinical research and for the companies that they represent, and so there were many opportunities for us to demonstrate how Huma can support clinical trials. Highlighting our digital expertise which is complimented but the capabilities we recently acquired with Alcedis, coming together to produce an enhanced DCT offering.”  

Based on your experience of the event, what opportunities are there for Huma to make a difference in this space? 

While traditional trials are still the go to for many companies we are seeing an increase in uptake and appetite for DCTs. This change in mindset is where we anticipate Huma making the most impact. Huma provides a patient-centric solution that also allows sponsors to build prototypes of their studies and engage their partners and key stakeholders ahead of the curve to iron out their differences. This should help increase adoption of remote patient monitoring technologies by increasing education (mock studies), garnering feedback through beta-study deployments in the build phase, thus resulting in an improved experience for everyone involved.

This field is required
This field is required
This field is required
This field is required
Thank you for your request.
You will receive an email from us shortly containing the file. Please check your inbox (and promotions tab or spam folder, if necessary) for the email.
Oops! Something went wrong while submitting the form

Contact us to discover more

Email must be formatted correctly
This field is required
This field is required
This field is required
This field is required
This field is required
Country/Region*
This field is required
I'm interested in

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

You’re in control. You can, of course, withdraw your consent at any time. Review our Privacy Policy for further information.

One of our team members will be in touch with you shortly.
Oops! Something went wrong while submitting the form.

Making an impact

3000+

3000+ hospitals and clinics supported across Huma platforms to secure the most sustainable impact for patients1

×2

Our platform can almost double clinical capacity and reduce readmission rates by >30%3

27m+

Huma's digital-first health platforms support a network of 27m patients1

1m+

Over 1 million devices have been shipped in support of our projects and we know what it takes to deploy at scale1

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Selected as one of 'The Most Important Healthcare Design of 2021' by Fast Company5

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Sources:

Blog

Exploring the future of De-centralized and Hybrid Trials: Huma at SCOPE 2023

February 24, 2023
Blog

Exploring the future of De-centralized and Hybrid Trials: Huma at SCOPE 2023

February 24, 2023

Huma joins digital pioneers to advance health equity in care and research

Chief Executive Officer and Founder, Dan Vahdat, is returning to the annual World Economic Forum’s main conference where he will join a panel discussion devoted to improving care for non-communicable disease and tackling health equity. Accompanied by Chief Financial and Strategy Officer, Ingeborg Oie, Dan is looking forward to connecting with other attendees to explore how Huma’s digital health platform can make healthcare more equitable, and advances proactive, predictive care.

Huma joins digital pioneers to advance health equity in care and research

Date:Wednesday, January 18, 2023
Time:4:15 - 5:15 p.m. CET
Location:Ice Village, Eisbahnstrasse 5, Davos, Switzerland
Dan will join the Digital Health Action Alliance panel at Davos to discuss Turning the Tide in Non-Communicable Disease Care Through Digital Health and Community Connection. Huma has a long history of advancing the care of non-communicable diseases (NCDs) such as heart disease, cancer, diabetes and lung conditions. Huma’s innovative remote patient monitoring platform enables broad patient recruitment, reduces reliance on in-person clinic visits and increases health system efficiency.
*This session is open to registered Annual Meeting 2023 participants and Affiliate badge holders.

Huma is one of the first to sign the Zero Health Gaps Pledge

Huma is one of the first signatories to the Zero Health Gaps Pledge, the World Economic Forum’s Global Health Equity Network’s (GHEN) initiative. Huma supports GHEN’s ambition to build a future without disparities in health or wellbeing outcomes. Huma’s digital platform has been built on a deep clinical knowledge of complex patient needs and how people engage with technology and we are committed to ensuring our technology promotes health equity. We are proud to work with governments, hospital groups, universities, life science and technology companies to bring greater scale and impact and help all people live longer, fuller lives.

Huma at World Economic Forum

Global Innovators and Tech Pioneers
Dec 2022: Huma selected to join 100 innovative companies on a two-year journey as part of the World Economic Forum’s initiatives, activities and events, bringing their cutting-edge insight and fresh thinking to critical global discussions.
Learn more
Working Together, Restoring Trust
May 2022: With the aim to address economic, environmental, political, and social fault-lines exacerbated by the COVID-19 pandemic, Dan Vahdat speaks at WEF annual meeting about the importance of scientific collaboration.
Learn more
Accelerating innovation and breaking new ground
October 2022: Dan joined the WEF Biotech Future Forum 2022 to discuss how start-ups are breaking new ground in biotech and changing the way we interact with the world, but also how the sector can earn trust, scale successfully and spot the brightest innovations.
Learn more
Making connections at Davos
Jan 2019: Dan attended WEF as an unofficial attendee and spoke to CNBC about the importance of meeting in-person to make connections.
Learn more

Related Articles

See more
Article
AI is in our DNA
Explore how Huma has been developing AI to revolutionise healthcare, and request a meeting with us to find out more.
Learn more
Article
“It’s really gold dust” Why Huma is a big step forward for knee surgery
Discover how Huma is providing Smith+Nephew with real world evidence for robotic knee replacement surgery.
Learn more

Related Blogs

See more
Blog
How Huma is transforming Health
Tim Broke-Smith, Huma's Vice President, Global Pharma Partnerships, considers how cutting edge technology can transform healthcare.
Learn more
Blog
Diabetes goes digital
Explore this blog featuring the Q&A session with Edith Giemula to uncover the ways in which digital tools are revolutionising diabetes research.
Learn more

Related Ebooks

See more
Ebook
Welcome to next-generation digital-first care and research
Deliver more personalised digital-first care and research with the first disease agnostic enterprise platform to achieve EU MDR Class IIb certification1.
Learn more
Ebook
What does FDA 510(k) Class II mean for Huma and our partners
Deliver more personalised digital-first care and research with our enterprise platform which now has FDA 510 (K) Class II clearance for any physician-specified condition.
Learn more

Related White Papers

See more
White Paper
Navigating the DCT transition
Learn how remote trial technology is changing the clinical trial landscape and key considerations when including DCT components in your study protocols.
Learn more
Blog

Exploring the future of De-centralized and Hybrid Trials: Huma at SCOPE 2023

February 24, 2023
Media contact
A headshot of Karen Birmingham PhD
Karen Birmingham PhD
Head of PR & Communications
karen.birmingham@huma.com
Blog

Exploring the future of De-centralized and Hybrid Trials: Huma at SCOPE 2023

February 24, 2023
Media contact
A headshot of Karen Birmingham PhD
Karen Birmingham PhD
Head of PR & Communications
karen.birmingham@huma.com

On the 6th February we saw the opening of SCOPE 2023 in Orlando, a summit for clinical ops executives and an opportunity to learn about the latest developments in decentralised clinical trials (DCT). Huma's DCT team was present at the event and shared insights on how digital is paving the way for DCTs. Themes from the event focused on the advancements of  innovative solutions in all aspects of clinical trials ranging from planning, management and operations. Attendees had the chance to learn and network with leading experts in the field and gain valuable insights into how to execute successful decentralised and hybrid trials.

We caught up Huma’s DCT team to get their take-home points from the event.

asdasd

asda

asdsads

asda

asdsad

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Download
Share this
COMPANY

About Huma

Huma began its journey in 2011, when the company was founded in London. Since then, Huma has grown to become a global healthcare company, spanning across multiple geographies and operating across four continents.

Learn more